|
CYR61 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.79589995599849E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.95110000062493E-09 |
| Normal-vs-Stage2 |
1.36769995329189E-09 |
| Normal-vs-Stage3 |
2.67980004853285E-09 |
| Normal-vs-Stage4 |
2.19740003970514E-10 |
| Stage1-vs-Stage2 |
1.664560E-01 |
| Stage1-vs-Stage3 |
3.503800E-01 |
| Stage1-vs-Stage4 |
5.477200E-03 |
| Stage2-vs-Stage3 |
6.233800E-01 |
| Stage2-vs-Stage4 |
3.534400E-01 |
| Stage3-vs-Stage4 |
1.022020E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.2777000003037E-09 |
| Normal-vs-AfricanAmerican |
2.3626999999804E-06 |
| Normal-vs-Asian |
5.21249998719497E-09 |
| Caucasian-vs-AfricanAmerican |
4.152200E-01 |
| Caucasian-vs-Asian |
8.982800E-01 |
| AfricanAmerican-vs-Asian |
4.962400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.03480002344725E-09 |
| Normal-vs-Female |
4.54159998497516E-09 |
| Male-vs-Female |
1.641580E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.40069997004389E-09 |
| Normal-vs-Age(41-60Yrs) |
2.65199995297394E-09 |
| Normal-vs-Age(61-80Yrs) |
1.24370003184993E-09 |
| Normal-vs-Age(81-100Yrs) |
1.339760E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.984600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.226800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.051000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.712400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.674400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.488000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.23100000000299E-05 |
| Classical-VS-Follicular |
2.326800E-01 |
| Classical-VS-Other |
9.023800E-01 |
| Classical-VS-Normal |
3.87929999234871E-09 |
| Tall-VS-Follicular |
3.989400E-04 |
| Tall-VS-Other |
2.542200E-01 |
| Tall-VS-Normal |
5.50539613897172E-11 |
| Follicular-VS-Other |
6.348000E-01 |
| Follicular-VS-Normal |
6.17730000485039E-08 |
| Other-VS-Normal |
1.36390000005093E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.59009999506554E-09 |
| Normal-vs-N1 |
1.93149995997288E-09 |
| N0-vs-N1 |
5.259800E-01 |
|
|
